Press release: CollimateHealth Targets Immune Responses Through Microbeam Therapy

CollimateHealth, a Munich-based life science start-up, has closed a seed funding round of six million. The company is developing a clinically scalable microbeam therapy which, unlike conventional radiation therapy, uses extremely focused beams at the micrometer scale with the goal of activating the body’s own immune system and significantly reducing side effects.

For more information: Read the full press release here.